June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Characterisation of an induced pluripotent stem cell derived retinal pigment epithelial line derived from a subject with a MerTK defect hereditary retinopathy.
Author Affiliations & Notes
  • Conor Ramsden
    UCL, London, United Kingdom
    Moorfields Eye Hospital, London, United Kingdom
  • Amanda-Jayne Francis Carr
    UCL, London, United Kingdom
  • Amelia Lane
    UCL, London, United Kingdom
  • Michael Powner
    UCL, London, United Kingdom
  • Britta Nommitse
    UCL, London, United Kingdom
  • Lyndon da Cruz
    Moorfields Eye Hospital, London, United Kingdom
  • Pete Coffey
    UCL, London, United Kingdom
  • Footnotes
    Commercial Relationships Conor Ramsden, None; Amanda-Jayne Carr, None; Amelia Lane, None; Michael Powner, None; Britta Nommitse, None; Lyndon da Cruz, None; Pete Coffey, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1836. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Conor Ramsden, Amanda-Jayne Francis Carr, Amelia Lane, Michael Powner, Britta Nommitse, Lyndon da Cruz, Pete Coffey; Characterisation of an induced pluripotent stem cell derived retinal pigment epithelial line derived from a subject with a MerTK defect hereditary retinopathy.. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1836.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Hereditary retinopathy is now the most common cause for blind registration in the working population in the UK. In order to combat this heterogenous group of diseases, adequate disease models need to be developed in order to better understand physiology and to test potential therapies. Our subject is a previously genotyped with two mutations in the MerTK gene, an established premature stop mutation in exon 14 and a previously unreported mutation in intron 1 which has been predicted to interfere with splicing. The MerTK protein is expressed on the apical surface of the RPE cells and is regarded as an essential component of the phagocytic machinery.

Methods: Using plasmids, the Yamanaka factors were expressed in the fibroblasts of a patient with RP38 to generate pluripotent stem cells. Using established protocols, these cells were driven towards an RPE fate. The cells were interrogated with antibodies to RPE markers and gene expression checked with reverse transcription PCR.

Results: The iPS derived RPE form pigmented monolayers and express the RPE genes PAX6, RPE65, OTX2, PMEL17, BEST, CRALBP and MERTK. Furthermore, all of these proteins were present except MerTK. The MerTK protein was noted to be present in a control line. The entire gene was amplified by PCR and the products of the PCR noted to be identical in size between the disease iPS line and the control line.

Conclusions: Using our tissue specific disease model, we dispute a previous prediction that the mutation in intron 1 interferes with splicing. Going forward, our intention is to use this disease model to further examine the role of MerTK in phagocytosis and test read through agents to gain expression of MerTK and ameliorate disease phenotype.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.